NCT05576571 is a clinical trial of Met-score in Serum Tumor Markers, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT05576571?

NCT05576571 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT05576571?

Interventions in NCT05576571: Met-score.

What condition does NCT05576571 study?

NCT05576571 studies Serum Tumor Markers.

Is NCT05576571 still recruiting?

NCT05576571 is currently status unknown. Last updated 17 October 2022.

Last reviewed 2022-10-17 · How we verify

NCT05576571

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma

Status unknown Last updated 17 October 2022

What this trial tests

trial testing Met-score in Serum Tumor Markers in 90 participants. Status unknown.

Timeline

16 October 2020

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	90
Start date	16 October 2020
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Taiwan

Drugs / interventions tested

Met-score

Conditions studied

Serum Tumor Markers — all drugs for Serum Tumor Markers →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 85, any sex, with Serum Tumor Markers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with liver cancer expected to undergo radiofrequency ablation or transvascular embolization. Relevant tumor markers (AFP and methylation analysis) were performed. The two data are then counted and compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05576571 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 17 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05576571.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing